Structural requirements at the N-terminus of urotensin II octapeptides

Peptides

Volumn 23, Issue 12, 2002, Pages 2259-2264

  Coy, D H ^a   Rossowski, W J ^a   Cheng, B L ^a   Taylor, J E ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Biomeasure Inc   (United States)

Author keywords

Human and rat urotensin II receptors; Rat aorta; Urotensin II structure activity relationships

Indexed keywords

AROMATIC AMINO ACID; HYDROXYL GROUP; NITRIC OXIDE; OCTAPEPTIDE; RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR; UROTENSIN II RECEPTOR BLOCKING AGENT;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG TARGETING; HYDROGEN BOND; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT;

ANIMALS; AORTA, THORACIC; ASPARAGINE; HUMANS; MALE; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; UROTENSINS;

PRIMATES;

EID: 0036953161     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00266-8     Document Type: Article

References (14)

1. Ames R.S., Saran H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M.et al. Human urotensin II is a potent vaso-constrictor and agonist for the orphan receptor GPR14. Nature. 401:1999;282-286.
2. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P.et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1982;1133-1140.
3. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C.et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15803-15808.
4. Coulouarn Y., Jegou S., Tostivint H., Vaudry H., Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett. 457:1999;28-32.
5. Flohr F., Kurz M., Kostenis E., Brkovitch A., Fournier A., Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 45:2002;1799-1805.
6. Gibson A. Complex effects of Gillichtys urotensin II on rat aortic strips. Br. J. Pharmacol. 91:1987;205-212.
7. Hocart S.J., Jain R., Murphy W.A., Taylor J.E., Morgan B., Coy D.H. Potent antagonists of somatostatin: synthesis and biology. J. Med. Chem. 41:1998;1146-1154.
8. Hocart S.J., Jain R., Murphy W.A., Taylor J.E., Coy D.H. Highly potent cyclic disulfide antagonists of somatostatin. J. Med. Chem. 42:1999;1863-1871.
9. Itoh H., Itoh Y., Rivier J., Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol. 252:1987;R361-R366.
10. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams D.L.et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. 266:1999;174-178.
11. Maguire J.J., Kuc R.E., Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 131:2000;441-446.
12. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N.et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 19:2001;2185-2190.
13. Rajaswaran W.G., Hocart S.J., Murphy W.A., Taylor J.E., Coy D.H. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J. Med. Chem. 44:2001;1305-1311.
14. Rossowski W.J., Cheng B.L., Taylor J.E., Datta R., Coy D.H. UrotensinII-induced rat aorta ring contractions mediated by protein kinase C, tyrosine kinases and rho-kinase: inhibition by SRIF-antagonists. Eur. J. Pharmacol. 438:2002;159-170.